Table 1.

Collected information of all patients who underwent esophageal atresia repair at the Montreal Children's Hospital between 2005 and 2023.

Demographic data	Sex, date and place of birth, gestational age, birth weight, Apgar score, date of admission to hospital, date of surgery
Prenatal data	Intrauterine growth delay
	Date of diagnosis of esophageal and/or tracheoesophageal fistula
	Multiple pregnancy
	In Vitro Fertilization
Additional anomalies	Skeletal, anorectal, cardiac, renal, limb, gastrointestinal, respiratory, other
Type of esophageal atresia	Gross classification
Syndromes	Vacterl, charge, Other
Gastrointestinal outcomes	Medications during first 5 years of life: proton pump inhibitors; cisapride; domperidone; H2 receptor blocking agents;
	Need for gavage feeding
	Esophageal pathology (esophagitis, barret's esophagus, Stenosis, Hiatal hernia, esophageal diverticulum);
	Stomach and duodenal pathology (ectopic pancreas, microgastria) and abnormal histology (peptic esophagitis, eosinophilic esophagitis, dilatation required)
Respiratory outcomes	Medications during first 5 years of life (antibiotics, per so steroids, inhalational steroids, ventolin)
	Deteriorations; admission to hospital (intensive care unit, emergency, ward);
	Diagnostics (pneumonia, bronchitis, sinusitis, asthma attack); abnormal respiratory symptoms (coughing, morning cough, night-time cough, grumbling breathing, grumbling (eating), wheezing, respond to ventolin); exertional dyspnea; continuous dosing aerosol (corticosteroids, without long-acting beta agonists, With long-acting beta agonists, other inhaler) and abnormal auscultation (rhonchi, crackles, wheezing)